secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0000950170-25-076911
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy
--------------------------------------------------------------------------------

- Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.
- Discontinues current POTENTIATE trial arms for BBI-355 due to narrow therapeutic index and poor tolerability.
- Plans to develop BBI-355/BBI-825 combination; initial clinical data expected within extended cash runway.
- Selects BBI-940 as Kinesin program candidate; IND submission expected first half 2026.
- Cash, equivalents & investments $138.3M as of March 31, 2025; operating runway extended into first half 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/0000950170-25-076911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/bold-20250523.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-076911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer